COVID-19 Update: Information and resources can be found here.

Chemistry and Cancer

22 members representing seven departments at UT Southwestern

The interdisciplinary Chemistry and Cancer (CC) Program is uniquely situated to bridge fundamental biology research with the discovery of novel therapies for the treatment of cancer. CC combines the expertise of synthetic and medicinal chemists, molecular and structural biologists, biochemists, chemical biologists, pharmacologists, and clinician scientists to discover, design, and optimize drug-like small molecules that regulate biological pathways deregulated in cancer. CC’s discovery platform is guided by the hypothesis that an interdisciplinary and chemically focused approach to cancer biology will provide new avenues for discovery in cancer prevention and treatment.

The CC Program is defined by three specific aims: Identification of Molecular Targets of Novel Anti-Cancer Agents; Biochemical Dissection of Regulatory Pathways Relevant to Human Cancer; and Structure-Based Design of Chemicals that Perturb Cancer-Relevant Signaling Pathways.

Identification of Molecular Targets of Novel Anti-Cancer Agents

APC Truncation is a Therapeutic Target for the Treatment of Colorectal Cancer

Despite advances in targeted anticancer therapies, there are still no small-molecule-based therapies that specifically target colorectal cancer (CRC), a major priority in our catchment area and the second leading cause of cancer deaths. Mutations in the adenomatous polyposis coli (APC) gene are common in CRC, and more than 90% of those mutations generate stable truncated gene products. Co-leader Jef De Brabander, Ph.D., and Jerry Shay, Ph.D. executed a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein, leading to the identification of a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares cells with wild-type APC.

Four white cells with varying amounts of dark spots on them

Biochemical Dissection of Regulatory Pathways Relevant to Human Cancer

Inhibition of Prostaglandin-Degrading Enzyme Stimulates Tissue Regeneration

Joseph Ready, Ph.D., and Bruce Posner, Ph.D., have established a multi-institute collaboration with Sanford Markowitz, M.D., and Stanton Gerson, M.D., from Case Western, to develop an inhibitor of the prostaglandin-degrading enzyme 15-PGDH for hematological malignancies. This interdisciplinary team of scientists identified a small-molecule inhibitor of 15-PGDH that increases prostaglandin PGE2 levels in bone marrow and other tissues.

Orange and red strands

Structure-Based Design of Chemicals that Perturb Cancer-Relevant Signaling Pathways

First-in-class inhibitor of HIF-2α is a targeted therapy for kidney cancer

Hypoxia Inducible Factors (HIFs) are heterodimeric transcription factors that are integral to the cellular hypoxic response pathway and sensing oxygen availability. HIFs are also implicated in cancer, which inspired a multi-PI initiative at UTSW to investigate these transcription factors as therapeutic targets. The team of scientists included Co-leader Uttam Tambar, Ph.D., and former program members Richard Bruick, Ph.D.; Kevin Gardner, Ph.D.; and John MacMillan, Ph.D. Although transcription factors are frequently described as 'undruggable' biological targets, scientists at UT Southwestern developed novel chemical strategies to generate artificial ligands that target HIF-2 in an isoform-selective manner.

White ribbons with red, blue, and white clumps of cells

Leadership

Jef De Brabander, Ph.D.

Professor, Biochemistry

De Brabander Lab

Jef De Brabander, Ph.D.

Uttam Tambar, Ph.D.

Associate Professor, Biochemistry

Tambar Lab

Uttam Tambar, Ph.D.